151 related articles for article (PubMed ID: 17512703)
1. In vitro activities of faropenem, ertapenem, imipenem and meropenem against Borrelia burgdorferi s.l.
Rödel R; Freyer A; Bittner T; Schäfer V; Hunfeld KP
Int J Antimicrob Agents; 2007 Jul; 30(1):83-6. PubMed ID: 17512703
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Wexler HM; Engel AE; Glass D; Li C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi.
Yang X; Nguyen A; Qiu D; Luft BJ
J Antimicrob Chemother; 2009 Apr; 63(4):709-12. PubMed ID: 19182236
[TBL] [Abstract][Full Text] [Related]
4. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi.
Ates L; Hanssen-Hübner C; Norris DE; Richter D; Kraiczy P; Hunfeld KP
Ticks Tick Borne Dis; 2010 Mar; 1(1):30-4. PubMed ID: 21771509
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
7. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
8. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
[TBL] [Abstract][Full Text] [Related]
10. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
Lemaire S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
J Antimicrob Chemother; 2005 Jun; 55(6):897-904. PubMed ID: 15860552
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of carbapenem antimicrobial agents against 264 penicillin-resistant Streptococcus pneumoniae isolates from Korea.
Choi SH; Park SJ; Jun JB; Lee SR; Jeon MH; Kwon HH; Kim SC; Kim MN; Jeong JY; Woo JH; Kim YS
Diagn Microbiol Infect Dis; 2007 May; 58(1):141-3. PubMed ID: 17368803
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.
Dever LL; Torigian CV; Barbour AG
Antimicrob Agents Chemother; 1999 Jul; 43(7):1773-5. PubMed ID: 10390242
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.
Kraiczy P; Weigand J; Wichelhaus TA; Heisig P; Backes H; Schäfer V; Acker G; Brade V; Hunfeld KP
Antimicrob Agents Chemother; 2001 Sep; 45(9):2486-94. PubMed ID: 11502519
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of Borrelia and Leptospira to Quinupristin-dalfopristin (Synercid) in vitro.
Murgia R; Cinco M
New Microbiol; 2001 Apr; 24(2):193-6. PubMed ID: 11346304
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of Borrelia afzelii strains to antimicrobial agents.
Ruzić-Sabljić E; Podreka T; Maraspin V; Strle F
Int J Antimicrob Agents; 2005 Jun; 25(6):474-8. PubMed ID: 15871918
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.
Sicklinger M; Wienecke R; Neubert U
J Clin Microbiol; 2003 Apr; 41(4):1791-3. PubMed ID: 12682190
[TBL] [Abstract][Full Text] [Related]
17. Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii.
Bantar C; Schell C; Posse G; Limansky A; Ballerini V; Mobilia L
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):309-14. PubMed ID: 18375084
[TBL] [Abstract][Full Text] [Related]
18. In vitro investigation of the indirect pathogenicity of beta-lactamase-producing microorganisms in the nasopharyngeal microflora.
Kaieda S; Yano H; Okitsu N; Hosaka Y; Okamoto R; Inoue M; Takahashi H
Int J Pediatr Otorhinolaryngol; 2005 Apr; 69(4):479-85. PubMed ID: 15763284
[TBL] [Abstract][Full Text] [Related]
19. Grapefruit seed extract is a powerful in vitro agent against motile and cystic forms of Borrelia burgdorferi sensu lato.
Brorson O; Brorson SH
Infection; 2007 Jun; 35(3):206-8. PubMed ID: 17565468
[No Abstract] [Full Text] [Related]
20. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances.
Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
Eur J Clin Microbiol Infect Dis; 2000 Jan; 19(1):27-32. PubMed ID: 10706176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
